Replies to post #110549 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

It is nice to see that others have figured out the routine.

[Solantey]

I think your assessment is pretty much on target.

If the LymPro data isn't substantially better than I expect it to be I expect the share price will drop towards the .05 range.

Questionable LymPro data and the impending dilution for the ESS deal will take it there.

Waiting to see if Gerald can pull it off.

p.s. Best place to hide the financing/dilution p.r. was Christmas eve.

[brharris]

The company issued an 8-k on 11/14 and 12/24 with combined total financing from those is $5 million, enough to close the ESS deal. The Series E shares are restricted for 6 months so the earliest any of those shares can come to market is May.

You can certainly claim dilution is holding the stock back but you can't logically claim that the company needs money to close the ESS deal when they announced the financing deals already.